Disease-Modifying Therapy
Children born with spinal muscular atrophy from 2016 on are living longer
Disease-modifying therapies introduced in Italy led to better outcomes and survival rates in children born after 2016 with type 1 spinal muscular atrophy compared with those born prior to then, new data published in EClinicalMedicine show.
Age, racial gaps in b/tsDMARD use for rheumatoid arthritis show ‘surprising’ stability
WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including among older, Black and Asian patients, have not changed in 10 years, according to data.
Long-term upadacitinib superior to methotrexate for rheumatoid arthritis
Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.
Safety checklist compiles clinically important DMARD warnings in one place
Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.
Extensive psoriasis, IBD history predict difficult-to-treat psoriatic arthritis
Difficult-to-treat psoriatic arthritis was common in a large, real-life cohort, with key risk factors including extensive psoriasis, higher BMI and a history of inflammatory bowel disease, according to data published in Rheumatology.
Dementia risk lower in patients with rheumatoid arthritis treated with biologic DMARDs
Dementia risk decreases among patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs, according to a systematic review and meta-analysis published in RMD Open.
Tapering csDMARDs in RA remission fails to achieve non-inferiority vs. stable dose
Patients in rheumatoid arthritis remission who tapered off conventional synthetic disease-modifying antirheumatic drugs had higher risks for flares, with two methods failing to reach non-inferiority vs. stable dosage, according to data.
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.
EULAR definition of difficult-to-treat rheumatoid arthritis leaves ‘some holes’
SAN DIEGO — The official EULAR definition of difficult-to-treat rheumatoid arthritis does not fully account for the problems the disease can present, according to a presenter at the Congress of Clinical Rheumatology West.